1
|
Ramaprasad A, Burda PC, Calvani E, Sait AJ, Palma-Duran SA, Withers-Martinez C, Hackett F, Macrae J, Collinson L, Gilberger TW, Blackman MJ. A choline-releasing glycerophosphodiesterase essential for phosphatidylcholine biosynthesis and blood stage development in the malaria parasite. eLife 2022; 11:e82207. [PMID: 36576255 PMCID: PMC9886279 DOI: 10.7554/elife.82207] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Accepted: 12/23/2022] [Indexed: 12/29/2022] Open
Abstract
The malaria parasite Plasmodium falciparum synthesizes significant amounts of phospholipids to meet the demands of replication within red blood cells. De novo phosphatidylcholine (PC) biosynthesis via the Kennedy pathway is essential, requiring choline that is primarily sourced from host serum lysophosphatidylcholine (lysoPC). LysoPC also acts as an environmental sensor to regulate parasite sexual differentiation. Despite these critical roles for host lysoPC, the enzyme(s) involved in its breakdown to free choline for PC synthesis are unknown. Here, we show that a parasite glycerophosphodiesterase (PfGDPD) is indispensable for blood stage parasite proliferation. Exogenous choline rescues growth of PfGDPD-null parasites, directly linking PfGDPD function to choline incorporation. Genetic ablation of PfGDPD reduces choline uptake from lysoPC, resulting in depletion of several PC species in the parasite, whilst purified PfGDPD releases choline from glycerophosphocholine in vitro. Our results identify PfGDPD as a choline-releasing glycerophosphodiesterase that mediates a critical step in PC biosynthesis and parasite survival.
Collapse
Affiliation(s)
- Abhinay Ramaprasad
- Malaria Biochemistry Laboratory, The Francis Crick InstituteLondonUnited Kingdom
| | - Paul-Christian Burda
- Centre for Structural Systems BiologyHamburgGermany
- Bernhard Nocht Institute for Tropical MedicineHamburgGermany
- University of HamburgHamburgGermany
| | - Enrica Calvani
- Metabolomics Science Technology Platform, The Francis Crick InstituteLondonUnited Kingdom
| | - Aaron J Sait
- Electron Microscopy Science Technology Platform, The Francis Crick InstituteLondonUnited Kingdom
| | | | | | - Fiona Hackett
- Malaria Biochemistry Laboratory, The Francis Crick InstituteLondonUnited Kingdom
| | - James Macrae
- Metabolomics Science Technology Platform, The Francis Crick InstituteLondonUnited Kingdom
| | - Lucy Collinson
- Electron Microscopy Science Technology Platform, The Francis Crick InstituteLondonUnited Kingdom
| | - Tim Wolf Gilberger
- Centre for Structural Systems BiologyHamburgGermany
- Bernhard Nocht Institute for Tropical MedicineHamburgGermany
- University of HamburgHamburgGermany
| | - Michael J Blackman
- Malaria Biochemistry Laboratory, The Francis Crick InstituteLondonUnited Kingdom
- Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical MedicineLondonUnited Kingdom
| |
Collapse
|
2
|
Tafenoquine Is a Promising Drug Candidate for the Treatment of Babesiosis. Antimicrob Agents Chemother 2021; 65:e0020421. [PMID: 33941516 DOI: 10.1128/aac.00204-21] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Due to drug resistance, commonly used anti-Babesia drugs have limited efficacy against babesiosis and inflict severe side effects. Tafenoquine (TAF) was approved by the U.S. Food and Drug Administration in 2018 for the radical cure of Plasmodium vivax infection and for malaria prophylaxis. Here, we evaluated the efficacy of TAF for the treatment of Babesia infection and elucidated the suspected mechanisms of TAF activity against Babesia parasites. Parasitemia and survival rates of Babesia rodhaini-infected BALB/c and SCID mice were used to explore the role of the immune response in Babesia infection after TAF treatment. Parasitemia, survival rates, body weight, vital signs, complete blood count, and blood biochemistry of B. gibsoni-infected splenectomized dogs were determined to evaluate the anti-Babesia activity and side effects of TAF. Then, to understand the mechanism of TAF activity, hydrogen peroxide was used as an oxidizer for short-term B. rodhaini incubation in vitro, and the expression levels of antioxidant enzymes were confirmed using B. microti-infected mice by reverse transcription-quantitative PCR (qRT-PCR). Acute B. rodhaini and B. gibsoni infections were rapidly eliminated with TAF administration. Repeated administration of TAF or a combination therapy with other antibabesial agents is still needed to avoid a potentially fatal recurrence for immunocompromised hosts. Caution about hyperkalemia should be taken during TAF treatment for Babesia infection. TAF possesses a babesicidal effect that may be related to drug-induced oxidative stress. Considering the lower frequency of glucose-6-phosphate dehydrogenase deficiency in animals compared to that in humans, TAF use on Babesia-infected farm animals and pets is eagerly anticipated.
Collapse
|
3
|
Tiwari MK, Chaudhary S. Artemisinin-derived antimalarial endoperoxides from bench-side to bed-side: Chronological advancements and future challenges. Med Res Rev 2020; 40:1220-1275. [PMID: 31930540 DOI: 10.1002/med.21657] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Revised: 11/21/2019] [Accepted: 12/17/2019] [Indexed: 12/14/2022]
Abstract
According to WHO World Malaria Report (2018), nearly 219 million new cases of malaria occurred and a total no. of 435 000 people died in 2017 due to this infectious disease. This is due to the rapid spread of parasite-resistant strains. Artemisinin (ART), a sesquiterpene lactone endoperoxide isolated from traditional Chinese herb Artemisia annua, has been recognized as a novel class of antimalarial drugs. The 2015 "Nobel Prize in Physiology or Medicine" was given to Prof Dr Tu Youyou for the discovery of ART. Hence, ART is termed as "Nobel medicine." The present review article accommodates insights from the chronological advancements and direct statistics witnessed during the past 48 years (1971-2019) in the medicinal chemistry of ART-derived antimalarial endoperoxides, and their clinical utility in malaria chemotherapy and drug discovery.
Collapse
Affiliation(s)
- Mohit K Tiwari
- Laboratory of Organic and Medicinal Chemistry, Department of Chemistry, Malaviya National Institute of Technology Jaipur, Jaipur, India
| | - Sandeep Chaudhary
- Laboratory of Organic and Medicinal Chemistry, Department of Chemistry, Malaviya National Institute of Technology Jaipur, Jaipur, India
| |
Collapse
|
4
|
Lumefantrine and o-choline - Parasite metabolism specific drug molecules inhibited in vitro growth of Theileria equi and Babesia caballi in MASP culture system. Ticks Tick Borne Dis 2019; 10:568-574. [PMID: 30733146 DOI: 10.1016/j.ttbdis.2019.01.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Revised: 01/10/2019] [Accepted: 01/20/2019] [Indexed: 01/01/2023]
Abstract
Theileria equi and Babesia caballi are tick-borne apicomplexan haemoprotozoan parasites of equines and are responsible for considerable economic losses to stakeholders. Chemotherapeutic drugs that are available not only require multiple dosages but also prompt multiple organ toxicity in treated host though incapable of clearing parasitaemia completely. In this study, we have screened the in vitro inhibitory efficacy of four different drug molecules (o-choline, DABCO®, lumefantrine and eugenol) against T. equi and B. caballi, targeting different parasite metabolism pathways. Imidocarb dipropionate and diminazene aceturate were used as reference control drugs. The 50% in vitro growth inhibitory concentration (IC50) of lumefantrine, o-choline, DABCO® and eugenol for T. equi were: 30.90 μM; 84.38 μM; 443 μM; 120 μM and for B. caballi growth inhibition were: 5.58 μM; 135.29 μM; 150 μM; 197.05 μM, respectively. Imidocarb dipropionate inhibited the in vitro growth of T. equi at IC50 of 257.5 nM, while diminazene aceturate inhibited the in vitro growth of B. caballi at IC50 of 22 nM. DABCO® and eugenol were not so effective in inhibiting the in vitro growth of T. equi and B. caballi, while lumefantrine and o-choline significantly (p ≤ 0.05) inhibited the in vitro growth of these piroplasms targeting haem digestion and parasite membrane phospholipid synthesis.
Collapse
|
5
|
High Accumulation and In Vivo Recycling of the New Antimalarial Albitiazolium Lead to Rapid Parasite Death. Antimicrob Agents Chemother 2017; 61:AAC.00352-17. [PMID: 28607017 DOI: 10.1128/aac.00352-17] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Accepted: 06/07/2017] [Indexed: 11/20/2022] Open
Abstract
Albitiazolium is the lead compound of bisthiazolium choline analogues and exerts powerful in vitro and in vivo antimalarial activities. Here we provide new insight into the fate of albitiazolium in vivo in mice and how it exerts its pharmacological activity. We show that the drug exhibits rapid and potent activity and has very favorable pharmacokinetic and pharmacodynamic properties. Pharmacokinetic studies in Plasmodium vinckei-infected mice indicated that albitiazolium rapidly and specifically accumulates to a great extent (cellular accumulation ratio, >150) in infected erythrocytes. Unexpectedly, plasma concentrations and the area under concentration-time curves increased by 15% and 69% when mice were infected at 0.9% and 8.9% parasitemia, respectively. Albitiazolium that had accumulated in infected erythrocytes and in the spleen was released into the plasma, where it was then available for another round of pharmacological activity. This recycling of the accumulated drug, after the rupture of the infected erythrocytes, likely extends its pharmacological effect. We also established a new viability assay in the P. vinckei-infected mouse model to discriminate between fast- and slow-acting antimalarials. We found that albitiazolium impaired parasite viability in less than 6 and 3 h at the ring and late stages, respectively, while parasite morphology was affected more belatedly. This highlights that viability and morphology are two parameters that can be differentially affected by a drug treatment, an element that should be taken into account when screening new antimalarial drugs.
Collapse
|
6
|
Eichenberger RM, Ramakrishnan C, Russo G, Deplazes P, Hehl AB. Genome-wide analysis of gene expression and protein secretion of Babesia canis during virulent infection identifies potential pathogenicity factors. Sci Rep 2017; 7:3357. [PMID: 28611446 PMCID: PMC5469757 DOI: 10.1038/s41598-017-03445-x] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2017] [Accepted: 04/27/2017] [Indexed: 12/14/2022] Open
Abstract
Infections of dogs with virulent strains of Babesia canis are characterized by rapid onset and high mortality, comparable to complicated human malaria. As in other apicomplexan parasites, most Babesia virulence factors responsible for survival and pathogenicity are secreted to the host cell surface and beyond where they remodel and biochemically modify the infected cell interacting with host proteins in a very specific manner. Here, we investigated factors secreted by B. canis during acute infections in dogs and report on in silico predictions and experimental analysis of the parasite’s exportome. As a backdrop, we generated a fully annotated B. canis genome sequence of a virulent Hungarian field isolate (strain BcH-CHIPZ) underpinned by extensive genome-wide RNA-seq analysis. We find evidence for conserved factors in apicomplexan hemoparasites involved in immune-evasion (e.g. VESA-protein family), proteins secreted across the iRBC membrane into the host bloodstream (e.g. SA- and Bc28 protein families), potential moonlighting proteins (e.g. profilin and histones), and uncharacterized antigens present during acute crisis in dogs. The combined data provides a first predicted and partially validated set of potential virulence factors exported during fatal infections, which can be exploited for urgently needed innovative intervention strategies aimed at facilitating diagnosis and management of canine babesiosis.
Collapse
Affiliation(s)
| | | | | | - Peter Deplazes
- Institute of Parasitology, University of Zurich, Zurich, Switzerland
| | - Adrian B Hehl
- Institute of Parasitology, University of Zurich, Zurich, Switzerland.
| |
Collapse
|
7
|
Abstract
In search of antiparasitic agents, we here identify arylmethylamino steroids as potent compounds and characterize more than 60 derivatives. The lead compound 1o is fast acting and highly active against intraerythrocytic stages of chloroquine-sensitive and resistant Plasmodium falciparum parasites (IC50 1–5 nM) as well as against gametocytes. In P. berghei-infected mice, oral administration of 1o drastically reduces parasitaemia and cures the animals. Furthermore, 1o efficiently blocks parasite transmission from mice to mosquitoes. The steroid compounds show low cytotoxicity in mammalian cells and do not induce acute toxicity symptoms in mice. Moreover, 1o has a remarkable activity against the blood-feeding trematode parasite Schistosoma mansoni. The steroid and the hydroxyarylmethylamino moieties are essential for antimalarial activity supporting a chelate-based quinone methide mechanism involving metal or haem bioactivation. This study identifies chemical scaffolds that are rapidly internalized into blood-feeding parasites. Steroid units can facilitate membrane permeation and bioavailability in drugs. Here, using a medicinal chemistry program, Krieg et al. identify an arylmethylamino steroid that kills Plasmodium parasites, likely through a chelate-based quinone methide mechanism, and has activity against Schistosoma mansoni.
Collapse
|
8
|
Jourdan J, Matile H, Reift E, Biehlmaier O, Dong Y, Wang X, Mäser P, Vennerstrom JL, Wittlin S. Monoclonal Antibodies That Recognize the Alkylation Signature of Antimalarial Ozonides OZ277 (Arterolane) and OZ439 (Artefenomel). ACS Infect Dis 2016; 2:54-61. [PMID: 26819968 PMCID: PMC4718528 DOI: 10.1021/acsinfecdis.5b00090] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2015] [Indexed: 11/29/2022]
Abstract
![]()
The
singular structure of artemisinin, with its embedded 1,2,4-trioxane
heterocycle, has inspired the discovery of numerous semisynthetic
artemisinin and structurally diverse synthetic peroxide antimalarials,
including ozonides OZ277 (arterolane) and OZ439 (artefenomel). Despite
the critical importance of artemisinin combination therapies (ACTs),
the precise mode of action of peroxidic antimalarials is not fully
understood. However, it has long been proposed that the peroxide bond
in artemisinin and other antimalarial peroxides undergoes reductive
activation by ferrous heme released during hemoglobin digestion to
produce carbon-centered radicals that alkylate heme and parasite proteins.
To probe the mode of action of OZ277 and OZ439, this paper now describes
initial studies with monoclonal antibodies that recognize the alkylation
signature (sum of heme and protein alkylation) of these synthetic
peroxides. Immunofluorescence experiments conducted with ozonide-treated
parasite cultures showed that ozonide alkylation is restricted to
the parasite, as no signal was found in the erythrocyte or its membrane.
In Western blot experiments with ozonide-treated Plasmodium
falciparum malaria parasites, distinct protein bands
were observed. Significantly, no protein bands were detected in parallel
Western blot experiments performed with lysates from ozonide-treated Babesia divergens, parasites that also proliferate
inside erythrocytes but, in contrast to P. falciparum, do not catabolize hemoglobin. However, subsequent immunoprecipitation
experiments with these antibodies failed to identify the P.
falciparum proteins alkylated by OZ277 and OZ439. To the
best of the authors’ knowledge, this shows for the first time
that antimalarial ozonides, such as the artemisinins, alkylate proteins
in P. falciparum.
Collapse
Affiliation(s)
- Joëlle Jourdan
- Swiss Tropical and Public Health Institute, Socinstrasse 57, CH-4002 Basel, Switzerland
- University of Basel, CH-4003 Basel, Switzerland
| | - Hugues Matile
- F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland
| | - Ellen Reift
- Swiss Tropical and Public Health Institute, Socinstrasse 57, CH-4002 Basel, Switzerland
- University of Basel, CH-4003 Basel, Switzerland
| | - Oliver Biehlmaier
- Imaging Core Facility, Biozentrum, University of Basel, CH-4003 Basel, Switzerland
| | - Yuxiang Dong
- College of Pharmacy, University of Nebraska Medical Center, 986025 Nebraska Medical
Center, Omaha, Nebraska 68198, United States
| | - Xiaofang Wang
- College of Pharmacy, University of Nebraska Medical Center, 986025 Nebraska Medical
Center, Omaha, Nebraska 68198, United States
| | - Pascal Mäser
- Swiss Tropical and Public Health Institute, Socinstrasse 57, CH-4002 Basel, Switzerland
- University of Basel, CH-4003 Basel, Switzerland
| | - Jonathan L. Vennerstrom
- College of Pharmacy, University of Nebraska Medical Center, 986025 Nebraska Medical
Center, Omaha, Nebraska 68198, United States
| | - Sergio Wittlin
- Swiss Tropical and Public Health Institute, Socinstrasse 57, CH-4002 Basel, Switzerland
- University of Basel, CH-4003 Basel, Switzerland
| |
Collapse
|
9
|
New insight into the mechanism of accumulation and intraerythrocytic compartmentation of albitiazolium, a new type of antimalarial. Antimicrob Agents Chemother 2014; 58:5519-27. [PMID: 25001307 DOI: 10.1128/aac.00040-14] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Bis-thiazolium salts constitute a new class of antihematozoan drugs that inhibit parasite phosphatidylcholine biosynthesis. They specifically accumulate in Plasmodium- and Babesia-infected red blood cells (IRBC). Here, we provide new insight into the choline analogue albitiazolium, which is currently being clinically tested against severe malaria. Concentration-dependent accumulation in P. falciparum-infected erythrocytes reached steady state after 90 to 120 min and was massive throughout the blood cycle, with cellular accumulation ratios of up to 1,000. This could not occur through a lysosomotropic effect, and the extent did not depend on the food vacuole pH, which was the case for the weak base chloroquine. Analysis of albitiazolium accumulation in P. falciparum IRBC revealed a high-affinity component that was restricted to mature stages and suppressed by pepstatin A treatment, and thus likely related to drug accumulation in the parasite food vacuole. Albitiazolium also accumulated in a second high-capacity component present throughout the blood cycle that was likely not related to the food vacuole and also observed with Babesia divergens-infected erythrocytes. Accumulation was strictly glucose dependent, drastically inhibited by H+/K+ and Na+ ionophores upon collapse of ionic gradients, and appeared to be energized by the proton-motive force across the erythrocyte plasma membrane, indicating the importance of transport steps for this permanently charged new type of antimalarial agent. This specific, massive, and irreversible accumulation allows albitiazolium to restrict its toxicity to hematozoa-infected erythrocytes. The intraparasitic compartmentation of albitiazolium corroborates a dual mechanism of action, which could make this new type of antimalarial agent resistant to parasite resistance.
Collapse
|
10
|
Wein S, Maynadier M, Bordat Y, Perez J, Maheshwari S, Bette-Bobillo P, Tran Van Ba C, Penarete-Vargas D, Fraisse L, Cerdan R, Vial H. Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate. Br J Pharmacol 2012; 166:2263-76. [PMID: 22471905 PMCID: PMC3437492 DOI: 10.1111/j.1476-5381.2012.01966.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND AND PURPOSE Choline analogues, a new type of antimalarials, exert potent in vitro and in vivo antimalarial activity. This has given rise to albitiazolium, which is currently in phase II clinical trials to cure severe malaria. Here we dissected its mechanism of action step by step from choline entry into the infected erythrocyte to its effect on phosphatidylcholine (PC) biosynthesis. EXPERIMENTAL APPROACH We biochemically unravelled the transport and enzymatic steps that mediate de novo synthesis of PC and elucidated how albitiazolium enters the intracellular parasites and affects the PC biosynthesis. KEY RESULTS Choline entry into Plasmodium falciparum-infected erythrocytes is achieved both by the remnant erythrocyte choline carrier and by parasite-induced new permeability pathways (NPP), while parasite entry involves a poly-specific cation transporter. Albitiazolium specifically prevented choline incorporation into its end-product PC, and its antimalarial activity was strongly antagonized by choline. Albitiazolium entered the infected erythrocyte mainly via a furosemide-sensitive NPP and was transported into the parasite by a poly-specific cation carrier. Albitiazolium competitively inhibited choline entry via the parasite-derived cation transporter and also, at a much higher concentration, affected each of the three enzymes conducting de novo synthesis of PC. CONCLUSIONS AND IMPLICATIONS Inhibition of choline entry into the parasite appears to be the primary mechanism by which albitiazolium exerts its potent antimalarial effect. However, the pharmacological response to albitiazolium involves molecular interactions with different steps of the de novo PC biosynthesis pathway, which would help to delay the development of resistance to this drug.
Collapse
Affiliation(s)
- S Wein
- Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR 5235, Université Montpellier II, Montpellier, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Peyrottes S, Caldarelli S, Wein S, Périgaud C, Pellet A, Vial H. Choline analogues in malaria chemotherapy. Curr Pharm Des 2012; 18:3454-66. [PMID: 22607139 PMCID: PMC3480700 DOI: 10.2174/138161212801327338] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2012] [Accepted: 03/09/2012] [Indexed: 12/03/2022]
Abstract
Emerging resistance against well-established anti-malaria drugs warrants the introduction of new therapeutic agents with original mechanisms of action. Inhibition of membrane-based phospholipid biosynthesis, which is crucial for the parasite, has thus been proposed as a novel and promising therapeutic strategy. This review compiles literature concerning the design and study of choline analogues and related cation derivatives as potential anti-malarials. It covers advances achieved over the last two decades and describes: the concept validation, the design and selection of a clinical candidate (Albitiazolium), back-up derivatives while also providing insight into the development of prodrug approaches.
Collapse
Affiliation(s)
- Suzanne Peyrottes
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247 CNRS-UM1-UM2, Université Montpellier 2, place E. Bataillon, 34095 Montpellier, France
| | - Sergio Caldarelli
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247 CNRS-UM1-UM2, Université Montpellier 2, place E. Bataillon, 34095 Montpellier, France
| | - Sharon Wein
- Dynamique des Intéractions Membranaires Normales et Pathologiques (DIMNP), UMR 5235 CNRS-UM2, Université Montpellier 2, place E. Bataillon, 34095 Montpellier, France
| | - Christian Périgaud
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247 CNRS-UM1-UM2, Université Montpellier 2, place E. Bataillon, 34095 Montpellier, France
| | - Alain Pellet
- Sanofi-Aventis, Research & Development, 195 route d’Espagne, BP 13669, 31036 Toulouse Cedex 1, France
| | - Henri Vial
- Dynamique des Intéractions Membranaires Normales et Pathologiques (DIMNP), UMR 5235 CNRS-UM2, Université Montpellier 2, place E. Bataillon, 34095 Montpellier, France
| |
Collapse
|
12
|
Tischer M, Pradel G, Ohlsen K, Holzgrabe U. Quaternary ammonium salts and their antimicrobial potential: targets or nonspecific interactions? ChemMedChem 2011; 7:22-31. [PMID: 22113995 DOI: 10.1002/cmdc.201100404] [Citation(s) in RCA: 213] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2011] [Revised: 10/28/2011] [Indexed: 11/07/2022]
Abstract
For more than 50 years dequalinium chloride has been used successfully as an antiseptic drug and disinfectant, particularly for clinical purposes. Given the success of dequalinium chloride, several series of mono- and bisquaternary ammonium compounds have been designed and reported to have improved antimicrobial activity. Furthermore, many of them exhibit high activity against mycobacteria and protozoa, especially against plasmodia. This review discusses the structure-activity relationships and the modes of action of the various series of (bis)quaternary ammonium compounds.
Collapse
Affiliation(s)
- Maximilian Tischer
- Institute of Pharmacy and Food Chemistry, University of Würzburg, Würzburg, Germany
| | | | | | | |
Collapse
|
13
|
Tilley L, Charman SA, Vennerstrom JL. Semisynthetic Artemisinin and Synthetic Peroxide Antimalarials. NEGLECTED DISEASES AND DRUG DISCOVERY 2011. [DOI: 10.1039/9781849733496-00033] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Since the discovery of the endoperoxide sesquiterpene lactone artemisinin, numerous second-generation semisynthetic artemisinins and synthetic peroxides have been prepared and tested for their antimalarial properties. Using a case-study approach, we describe the discovery of the investigational semisynthetic artemisinins artelinic acid (8) and artemisone (9), and the structurally diverse synthetic peroxides arteflene (10), fenozan B07 (11), arterolane (12), PA1103/SAR116242 (13), and RKA182 (14).
Collapse
Affiliation(s)
- Leann Tilley
- Department of Biochemistry and Centre of Excellence for Coherent X-rayScience, La Trobe University Melbourne, Victoria 3086 Australia
| | - Susan A. Charman
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052 Australia
| | - Jonathan L. Vennerstrom
- College of Pharmacy University of Nebraska Medical Center, 986025 Nebraska Medical Center, Omaha NE USA
| |
Collapse
|
14
|
González-Bulnes P, Bobenchik AM, Augagneur Y, Cerdan R, Vial HJ, Llebaria A, Ben Mamoun C. PG12, a phospholipid analog with potent antimalarial activity, inhibits Plasmodium falciparum CTP:phosphocholine cytidylyltransferase activity. J Biol Chem 2011; 286:28940-28947. [PMID: 21705805 DOI: 10.1074/jbc.m111.268946] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
In the human malaria parasite Plasmodium falciparum, the synthesis of the major and essential membrane phospholipid, phosphatidylcholine, occurs via the CDP-choline and the serine decarboxylase phosphoethanolamine methylation (SDPM) pathways, which are fueled by host choline, serine, and fatty acids. Both pathways share the final two steps catalyzed by two essential enzymes, P. falciparum CTP:phosphocholine cytidylyltransferase (PfCCT) and choline-phosphate transferase (PfCEPT). We identified a novel class of phospholipid mimetics, which inhibit the growth of P. falciparum as well as Leishmania and Trypanosoma species. Metabolic analyses showed that one of these compounds, PG12, specifically blocks phosphatidylcholine biosynthesis from both the CDP-choline and SDPM pathways via inhibition of PfCCT. In vitro studies using recombinant PfCCT showed a dose-dependent inhibition of the enzyme by PG12. The potent antimalarial of this compound, its low cytotoxicity profile, and its established mode of action make it an excellent lead to advance for further drug development and efficacy in vivo.
Collapse
Affiliation(s)
- Patricia González-Bulnes
- Research Unit on BioActive Molecules (RUBAM), Departament de Química Biomèdica, Instituto de Química Avanzada de Cataluña IQAC, CSIC, Jordi Girona 18-26, 08034 Barcelona, Spain
| | - April M Bobenchik
- Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520, and
| | - Yoann Augagneur
- Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520, and
| | - Rachel Cerdan
- Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR 5235, Universite Montpellier II, 34095 Montpellier, France
| | - Henri J Vial
- Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR 5235, Universite Montpellier II, 34095 Montpellier, France
| | - Amadeu Llebaria
- Research Unit on BioActive Molecules (RUBAM), Departament de Química Biomèdica, Instituto de Química Avanzada de Cataluña IQAC, CSIC, Jordi Girona 18-26, 08034 Barcelona, Spain,.
| | - Choukri Ben Mamoun
- Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520, and.
| |
Collapse
|
15
|
Ibrahim HMS, Al-Salabi MI, El Sabbagh N, Quashie NB, Alkhaldi AAM, Escale R, Smith TK, Vial HJ, de Koning HP. Symmetrical choline-derived dications display strong anti-kinetoplastid activity. J Antimicrob Chemother 2010; 66:111-25. [PMID: 21078603 DOI: 10.1093/jac/dkq401] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
OBJECTIVES to investigate the anti-kinetoplastid activity of choline-derived analogues with previously reported antimalarial efficacy. METHODS from an existing choline analogue library, seven antimalarial compounds, representative of the first-, second- and third-generation analogues previously developed, were assessed for activity against Trypanosoma and Leishmania spp. Using a variety of techniques, the effects of choline analogue exposure on the parasites were documented and a preliminary investigation of their mode of action was performed. RESULTS the activities of choline-derived compounds against Trypanosoma brucei and Leishmania mexicana were determined. The compounds displayed promising anti-kinetoplastid activity, particularly against T. brucei, to which 4/7 displayed submicromolar EC(50) values for the wild-type strain. Low micromolar concentrations of most compounds cleared trypanosome cultures within 24-48 h. The compounds inhibit a choline transporter in Leishmania, but their entry may not depend only on this carrier; T. b. brucei lacks a choline carrier and the mode of uptake remains unclear. The compounds had no effect on the overall lipid composition of the cells, cell cycle progression or cyclic adenosine monophosphate production or short-term effects on intracellular calcium levels. However, several of the compounds, displayed pronounced effects on the mitochondrial membrane potential; this action was not associated with production of reactive oxygen species but rather with a slow rise of intracellular calcium levels and DNA fragmentation. CONCLUSIONS the choline analogues displayed strong activity against kinetoplastid parasites, particularly against T. b. brucei. In contrast to their antimalarial activity, they did not act on trypanosomes by disrupting choline salvage or phospholipid metabolism, instead disrupting mitochondrial function, leading to chromosomal fragmentation.
Collapse
Affiliation(s)
- Hasan M S Ibrahim
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Santos-Magalhães NS, Mosqueira VCF. Nanotechnology applied to the treatment of malaria. Adv Drug Deliv Rev 2010; 62:560-75. [PMID: 19914313 DOI: 10.1016/j.addr.2009.11.024] [Citation(s) in RCA: 152] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/14/2009] [Indexed: 12/24/2022]
Abstract
Despite the fact that we live in an era of advanced technology and innovation, infectious diseases, like malaria, continue to be one of the greatest health challenges worldwide. The main drawbacks of conventional malaria chemotherapy are the development of multiple drug resistance and the non-specific targeting to intracellular parasites, resulting in high dose requirements and subsequent intolerable toxicity. Nanosized carriers have been receiving special attention with the aim of minimizing the side effects of drug therapy, such as poor bioavailability and the selectivity of drugs. Several nanosized delivery systems have already proved their effectiveness in animal models for the treatment and prophylaxis of malaria. A number of strategies to deliver antimalarials using nanocarriers and the mechanisms that facilitate their targeting to Plasmodium spp.-infected cells are discussed in this review. Taking into account the peculiarities of malaria parasites, the focus is placed particularly on lipid-based (e.g., liposomes, solid lipid nanoparticles and nano and microemulsions) and polymer-based nanocarriers (nanocapsules and nanospheres). This review emphasizes the main requirements for developing new nanotechnology-based carriers as a promising choice in malaria treatment, especially in the case of severe cerebral malaria.
Collapse
|
17
|
Ahiboh H, Djaman AJ, Yapi FH, Edjeme-Aké A, Hauhouot-Attoungbré ML, Yayo ED, Monnet D. Effect of a bis-thiazolium compound on the biosynthesis of Plasmodium falciparum phospholipids. J Enzyme Inhib Med Chem 2009; 24:911-7. [DOI: 10.1080/14756360802447974] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Affiliation(s)
- Hugues Ahiboh
- Département de Biochimie Biologie Moléculaire, UFR des Sciences Pharmaceutiques et Biologiques, Université de Cocody – Abidjan BP V34
| | - Allico J Djaman
- Laboratoire de Pharmacodynamie Biochimique – UFR de Biosciences, Université de Cocody – Abidjan BP V34
- Département de Biochimie Fondamentale et Clinique – Institut Pasteur de Côte d’Ivoire – 01 BP 490 Abidjan 01
| | - Félix H Yapi
- Laboratoire de Pharmacodynamie Biochimique – UFR de Biosciences, Université de Cocody – Abidjan BP V34
| | - Angèle Edjeme-Aké
- Département de Biochimie Biologie Moléculaire, UFR des Sciences Pharmaceutiques et Biologiques, Université de Cocody – Abidjan BP V34
- Département de Biochimie Fondamentale et Clinique – Institut Pasteur de Côte d’Ivoire – 01 BP 490 Abidjan 01
| | - Marie-Laure Hauhouot-Attoungbré
- Département de Biochimie Biologie Moléculaire, UFR des Sciences Pharmaceutiques et Biologiques, Université de Cocody – Abidjan BP V34
| | - Eric D Yayo
- Département de Biochimie Biologie Moléculaire, UFR des Sciences Pharmaceutiques et Biologiques, Université de Cocody – Abidjan BP V34
| | - Dagui Monnet
- Département de Biochimie Biologie Moléculaire, UFR des Sciences Pharmaceutiques et Biologiques, Université de Cocody – Abidjan BP V34
| |
Collapse
|
18
|
Ben Mamoun C, Prigge ST, Vial H. Targeting the Lipid Metabolic Pathways for the Treatment of Malaria. Drug Dev Res 2009; 71:44-55. [PMID: 20559451 DOI: 10.1002/ddr.20347] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The control and eventual eradication of human malaria is considered one of the most important global public health goals of the 21st Century. Malaria, caused by intraerythrocytic protozoan parasites of the genus Plasmodium, is by far the most lethal and among the most prevalent of the infectious diseases. Four species of Plasmodium (P. falciparum, P. malariae, P. ovale, and P. vivax) are known to be infectious to humans, and more recent cases of infection due to P. knowlesi also have been reported. These species cause approximately 300 million annual cases of clinical malaria resulting in around one million deaths mostly caused by P. falciparum. The rapid emergence of drug-resistant Plasmodium strains has severely reduced the potency of medicines commonly used to treat and block the transmission of malaria and threatens the effectiveness of combination therapy in the field. New drugs that target important parasite functions, which are not the target of current antimalarial drugs, and have the potential to act against multi-drug-resistant Plasmodium strains are urgently needed. Recent studies in P. falciparum have unraveled new metabolic pathways for the synthesis of the parasite phospholipids and fatty acids. The present review summarizes our current understanding of these pathways in Plasmodium development and pathogenesis, and provides an update on the efforts underway to characterize their importance using genetic means and to develop antimalarial therapies targeting lipid metabolic pathways.
Collapse
Affiliation(s)
- Choukri Ben Mamoun
- Section of Infectious Disease, Yale University School of Medicine, New Haven, Connecticut
| | | | | |
Collapse
|
19
|
Le Roch KG, Johnson JR, Ahiboh H, Chung DWD, Prudhomme J, Plouffe D, Henson K, Zhou Y, Witola W, Yates JR, Mamoun CB, Winzeler EA, Vial H. A systematic approach to understand the mechanism of action of the bisthiazolium compound T4 on the human malaria parasite, Plasmodium falciparum. BMC Genomics 2008; 9:513. [PMID: 18973684 PMCID: PMC2596145 DOI: 10.1186/1471-2164-9-513] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2008] [Accepted: 10/30/2008] [Indexed: 11/25/2022] Open
Abstract
Background In recent years, a major increase in the occurrence of drug resistant falciparum malaria has been reported. Choline analogs, such as the bisthiazolium T4, represent a novel class of compounds with strong potency against drug sensitive and resistant P. falciparum clones. Although T4 and its analogs are presumed to target the parasite's lipid metabolism, their exact mechanism of action remains unknown. Here we have employed transcriptome and proteome profiling analyses to characterize the global response of P. falciparum to T4 during the intraerythrocytic cycle of this parasite. Results No significant transcriptional changes were detected immediately after addition of T4 despite the drug's effect on the parasite metabolism. Using the Ontology-based Pattern Identification (OPI) algorithm with an increased T4 incubation time, we demonstrated cell cycle arrest and a general induction of genes involved in gametocytogenesis. Proteomic analysis revealed a significant decrease in the level of the choline/ethanolamine-phosphotransferase (PfCEPT), a key enzyme involved in the final step of synthesis of phosphatidylcholine (PC). This effect was further supported by metabolic studies, which showed a major alteration in the synthesis of PC from choline and ethanolamine by the compound. Conclusion Our studies demonstrate that the bisthiazolium compound T4 inhibits the pathways of synthesis of phosphatidylcholine from choline and ethanolamine in P. falciparum, and provide evidence for post-transcriptional regulations of parasite metabolism in response to external stimuli.
Collapse
Affiliation(s)
- Karine G Le Roch
- Department of Cell Biology and Neuroscience, University of California, Riverside, 900 University Avenue, Riverside, CA 92521, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Fidock DA, Eastman RT, Ward SA, Meshnick SR. Recent highlights in antimalarial drug resistance and chemotherapy research. Trends Parasitol 2008; 24:537-44. [PMID: 18938106 DOI: 10.1016/j.pt.2008.09.005] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2008] [Revised: 09/15/2008] [Accepted: 09/16/2008] [Indexed: 01/07/2023]
Abstract
This review summarizes recent investigations into antimalarial drug resistance and chemotherapy, including reports of some of the many exciting talks and posters on this topic that were presented at the third Molecular Approaches to Malaria meeting held in Lorne, Australia, in February 2008 (MAM 2008). After surveying this area of research, we focus on two important questions: what is the molecular contribution of pfcrt to chloroquine resistance, and what is the mechanism of action of artemisinin? We conclude with thoughts about the current state of antimalarial chemotherapy and priorities moving forward.
Collapse
Affiliation(s)
- David A Fidock
- Department of Microbiology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
| | | | | | | |
Collapse
|
21
|
Sherman IW. References. ADVANCES IN PARASITOLOGY 2008. [DOI: 10.1016/s0065-308x(08)00430-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
22
|
Kaiser M, Wittlin S, Nehrbass-Stuedli A, Dong Y, Wang X, Hemphill A, Matile H, Brun R, Vennerstrom JL. Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160). Antimicrob Agents Chemother 2007; 51:2991-3. [PMID: 17562801 PMCID: PMC1932508 DOI: 10.1128/aac.00225-07] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Using nonperoxidic analogs of artemisinin and OZ277 (RBx11160), the strong in vitro antiplasmodial activities of the latter two compounds were shown to be peroxide bond dependent. In contrast, the weak activities of artemisinin and OZ277 against six other protozoan parasites were peroxide bond independent. These data support the iron-dependent artemisinin alkylation hypothesis.
Collapse
|